

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM395469

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	Security Agreement by Foreclosure		
RESUBMIT DOCUMENT ID:	900372545		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Urologix, Inc.		01/29/2016	Corporation:
RECEIVING PARTY DATA			
Name:	Project Trojan IP Acquisition, LLC		
Street Address:	5171 Clareton Drive		
City:	Agoura Hills		
State/Country:	CALIFORNIA		
Postal Code:	91301		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Serial Number:	78394674	COOLWAVE	
Serial Number:	77311966	CTC ADVANCE	
Serial Number:	73801523	PROSTATRON	
Serial Number:	75351846	TARGIS	
Serial Number:	74261868	UROLOGIX	
Serial Number:	74708152		
Serial Number:	73838022	TUMT	
CORRESPONDENCE DATA			
Fax Number:	3103273466		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	310 755-7800		
Email:	abarrett@inskeeplaw.com		
Correspondent Name:	Inskeep IP Group, Inc.		
Address Line 1:	2281 W. 190th Street, Suite 200		
Address Line 4:	Torrance, CALIFORNIA 90504		
ATTORNEY DOCKET NUMBER:	145233-201		
NAME OF SUBMITTER:	James W. Inskeep, Esq.		

SIGNATURE:	/James W. Inskeep/
DATE SIGNED:	08/17/2016
Total Attachments: 41	
source=PTIPA 201 2016-07-26 Resp to Notice of Non-Recordation of Assignment#page1.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page1.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page2.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page3.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page4.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page5.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page6.tif	
source=1_23.b. -Medtronic_Urologix_-_Notice_of_Grant_of_Security_Interest_in_Trademarks#page7.tif	
source=2_23 f - Voluntary Surrender Agreement#page1.tif	
source=2_23 f - Voluntary Surrender Agreement#page2.tif	
source=2_23 f - Voluntary Surrender Agreement#page3.tif	
source=2_23 f - Voluntary Surrender Agreement#page4.tif	
source=2_23 f - Voluntary Surrender Agreement#page5.tif	
source=2_23 f - Voluntary Surrender Agreement#page6.tif	
source=2_23 f - Voluntary Surrender Agreement#page7.tif	
source=2_23 f - Voluntary Surrender Agreement#page8.tif	
source=2_23 f - Voluntary Surrender Agreement#page9.tif	
source=2_23 f - Voluntary Surrender Agreement#page10.tif	
source=2_23 f - Voluntary Surrender Agreement#page11.tif	
source=2_23 f - Voluntary Surrender Agreement#page12.tif	
source=3_23.a.ix - Intellectual Property Assignment#page1.tif	
source=3_23.a.ix - Intellectual Property Assignment#page2.tif	
source=3_23.a.ix - Intellectual Property Assignment#page3.tif	
source=3_23.a.ix - Intellectual Property Assignment#page4.tif	
source=3_23.a.ix - Intellectual Property Assignment#page5.tif	
source=3_23.a.ix - Intellectual Property Assignment#page6.tif	
source=3_23.a.ix - Intellectual Property Assignment#page7.tif	
source=3_23.a.ix - Intellectual Property Assignment#page8.tif	
source=3_23.a.ix - Intellectual Property Assignment#page9.tif	
source=3_23.a.ix - Intellectual Property Assignment#page10.tif	
source=3_23.a.ix - Intellectual Property Assignment#page11.tif	
source=3_23.a.ix - Intellectual Property Assignment#page12.tif	
source=3_23.a.ix - Intellectual Property Assignment#page13.tif	
source=3_23.a.ix - Intellectual Property Assignment#page14.tif	
source=3_23.a.ix - Intellectual Property Assignment#page15.tif	
source=3_23.a.ix - Intellectual Property Assignment#page16.tif	
source=3_23.a.ix - Intellectual Property Assignment#page17.tif	
source=3_23.a.ix - Intellectual Property Assignment#page18.tif	
source=3_23.a.ix - Intellectual Property Assignment#page19.tif	
source=3_23.a.ix - Intellectual Property Assignment#page20.tif	
source=3_23.a.ix - Intellectual Property Assignment#page21.tif	

Response to Notice of Non-Recordation of Assignment dated May 19, 2016

On December 21, 2015, Urologix, Inc., the assignee of record for the marks that are the subject of this recordation request, granted Medtronic, Inc. a security interest in said marks as documented in the attached TM Security Interest document. Medtronic, Inc. subsequently initiated foreclosure proceedings against said marks based on the rights granted via the security interest. As a result of those foreclosure proceedings, rights in the marks were surrendered by the assignee to Medtronic, Inc. as documented by the attached Voluntary Surrender Agreement dated January 29, 2016. By virtue of its rights under the Voluntary Surrender Agreement, Medtronic, Inc. then assigned rights in said marks from the current assignee, Urologix, Inc. to the current owner, Project Trojan IP Acquisition, LLC, via the attached IP Assignment document dated January 29, 2016.

Based on the foregoing, the undersigned requests recordation of the assignment of said marks as originally submitted on May 10, 2016.

**NOTICE
OF
GRANT OF SECURITY INTEREST
IN
TRADEMARKS**

Dated: December [2], 2015

United States Patent and Trademark Office

Ladies and Gentlemen:


Please be advised that pursuant to a certain Security Agreement dated as of June 28, 2013 by and between Urologix, Inc., a Minnesota corporation, as debtor ("Debtor"), and Medtronic, Inc., a Minnesota corporation, as secured creditor ("Creditor"), as amended by a certain Forbearance Agreement and Amendment to Security Agreement dated as of December 8, 2015 (as amended, and as the same may hereafter be amended, modified, extended or restated from time to time, the "Security Agreement"), Debtor has granted to Creditor a continuing security interest in and continuing lien upon, among other things, all of such Debtor's trademarks and trademark applications, including without limitation those set forth on Schedule A hereto.

Each of Debtor and Creditor hereby acknowledges and agrees that the security interest in the foregoing trademarks and trademark applications is not to be construed as an assignment of any trademark or trademark application.

*[Remainder of page intentionally blank;
signature pages follow]*

IN WITNESS WHEREOF, this Notice of Grant of Security Interest in Trademarks has been duly executed by the Debtor as of the date first above written.

UROLOGIX, INC.,
a Minnesota corporation

By: 
Name: Greg Fleet
Title: CEO

[Signature page to Notice of Grant of Security Interest in Trademarks]

Acknowledged and accepted:

MEDTRONIC, INC.,
a Minnesota corporation

By: 
Name: Tom Tefft
Title: Senior Vice President

[Signature page to Notice of Grant of Security Interest in Trademarks]

SCHEDULE A

TRADEMARKS

(Includes website domains and copyrights)

(a) Registered Trademarks:

TRADEMARK	FILED	APPL#	REG DATE	REG#	STATUS
COOLWAVE					
UNITED STATES	4/1/2004	78/394,674	8/7/2007	3,276,185	REGISTERED
CTC ADVANCE					
UNITED STATES	10/24/2007	77/311,966	1/6/2009	3,558,641	REGISTERED
PROSTATRON					
UNITED STATES	5/22/1989	73/801,253	11/20/2000	1,623,355	REGISTERED
TARGIS					
UNITED STATES	9/4/1997	75/351,846	11/6/2001	2,504,853	REGISTERED
UROLOGIX					
CANADA	9/9/1994	763,755	11/24/1995	TMA450,772	REGISTERED
FRANCE	9/8/1994	8835	9/8/1994	94/535923	REGISTERED
JAPAN	4/5/1994	33544/94	5/23/1997	3312380	REGISTERED
UNITED STATES	4/2/1992	74/261,868	9/7/1993	1,792,148	REGISTERED
UROLOGIX CIRCLE LOGO					
UNITED STATES	7/31/1995	74/708,152	4/1/1997	2,049,865	REGISTERED
TUMT					
UNITED STATES	11/9/1989	73/838,022	12/25/1990	1,628,985	REGISTERED

Other OUS Trademarks (Abandoned):

UROLOGIX	SE	UROLOGIX AB	2009-04925	24-Jun-2009
PROSTATRON	FR	UROLOGIX, INC.	1501018	30-Nov-1988
PROSTATRON	CH	UROLOGIX, INC.	CHTM.062662001	2001-06-25
TUMT	CH	UROLOGIX, INC.	CHTM.062672001	2001-06-25
UROLOGIX	DE	Urologix, Inc.	DETM.DE290744 1	1994-09-06
PROSTATRON	SG	UROLOGIX, INC.	SGTM.T9110781I	1991-12-06

Non-registered Trademarks:

Cooled ThermoTherapy
Prostaprobe

Website Domains:

<u>Domain Name</u>	<u>Registered with:</u>	<u>Expires on:</u>
Urologixmobile.com	godaddy.com	8/6/2016
Helpmyprostate.com	godaddy.com	10/29/2017
CTTvideo.com	godaddy.com	4/26/2018
Prostivavideo.com	godaddy.com	4/26/2018
beat-bph.com	Networksolutions.com	5/24/2016
beatbph.com	Networksolutions.com	3/28/2018
bph-treatment.com	Networksolutions.com	6/19/2016
cooledmicrowavethermotherapy.com	Networksolutions.com	10/12/2020
cooledthermotherapy.com	Networksolutions.com	10/12/2020
getoffyourmeds.com	Networksolutions.com	9/7/2017
getoutofthebathroom.com	Networksolutions.com	9/7/2017
prostiva.com	Networksolutions.com	8/1/2016
takecontrolofyourflow.com	Networksolutions.com	8/27/2018
targis.com	Networksolutions.com	9/2/2016
urologix.com	Networksolutions.com	7/28/2016
urologixcertificates.com	Networksolutions.com	7/24/2018
vidamed.com	Networksolutions.com	11/16/2017
beat-bph.com	Networksolutions.com	5/24/2016

(b) Copyrights:

The following video clips are copyrighted by Urologix, Inc.:

<u>Video Name</u>	<u>Release Date</u>
InView Segment	4/5/2014
Real Patients Talk About BPH and Cooled ThermoTherapy™ Treatment HD	10/31/2013
Procedure Overview: Modified Periprostatic Nerve Block (with J. Randolph Beahrs M.D., F.A.C.S.)	10/8/2013
FAQ: What is the potential impact on my sexual function?	7/25/2013
FAQ: What are the long term outcomes?	7/25/2013
FAQ: What are the treatment options?	7/25/2013
FAQ: What are the long term risks?	7/25/2013
FAQ: IS BPH life threatening?	7/25/2013
FAQ: What is BPH?	7/25/2013
CTT Animation	7/15/2013
Prostiva Animation	7/15/2013
The Prostiva® Procedure: Mark And Shelly's Story	6/11/2013
The Balancing Act Segment	6/4/2013
Dr. Craig Smith: Patient 1 (3-5-2013) Prostiva® Procedure	6/4/2013
Dr. Craig Smith: Patient 4 (3-5-2013) Prostate Block	6/4/2013
Dr. Craig Smith: Patient 4 (3-5-2013) Prostiva® Procedure	6/4/2013

Video Name	Release Date
Dr. Craig Smith: Patient 3 (3-5-2013) Prostiva® Procedure	6/4/2013
Dr. Craig Smith: Patient 3 (3-5-2013) Prostate Block	6/4/2013
Dr. Craig Smith: Patient 2 (3-5-2013) Prostate Block	6/4/2013
Dr. Craig Smith: Patient 1 (3-5-2013) Prostate Block	6/4/2013
Dr. Randy Beahrs: Patient (3-26-2013) Prostate Block	6/4/2013
SESAUA March 2013 Conference Symposium	4/5/2013
Roland W. - After Having In-Office BPH Therapy	4/4/2013
Roland W. - Discusses His In-Office BPH Procedure	4/4/2013
Roland W. - Before Having In-Office BPH Therapy	4/4/2013
Doug K. - After Having In-Office BPH Therapy	4/4/2013
Doug K. - Discusses His In-Office BPH Procedure	4/4/2013
Doug K. - Before Having In-Office BPH Therapy	4/4/2013
Dean N. - After Having In-Office BPH Therapy	4/4/2013
Dean N. - Discusses His In-Office BPH Procedure	4/4/2013
Dean N. - Before Having In-Office BPH Therapy	4/4/2013
Bill K. - After Having In-Office BPH Therapy	4/4/2013
Bill K. - Discusses His In-Office BPH Procedure	4/4/2013
Bill K. - Before Having In-Office BPH Therapy	4/4/2013
Cooled ThermoTherapy Patient Education	3/22/2013
Prostiva® RF Therapy Patient Education	12/21/2012
Explore In-Office BPH Therapy	9/17/2012
About Benign Prostatic Hyperplasia	9/17/2012
Prostiva® RF Therapy Procedure	9/11/2012
Cooled ThermoTherapy™ Procedure	9/11/2012
Patients' Perspectives: Having In-Office BPH Therapy	9/7/2012
Paul A. - Life After In-Office BPH Therapy	9/7/2012
Paul A. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Paul A. - Life Before In-Office BPH Therapy	9/7/2012
John H. - Life After In-Office BPH Therapy	9/7/2012
John H. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
John H. - Life Before In-Office BPH Therapy	9/7/2012
Eric J. - Life After In-Office BPH Therapy	9/7/2012
Eric J. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Eric J. - Life Before In-Office BPH Therapy	9/7/2012
Thomas F. - Life After In-Office BPH Therapy	9/7/2012
Thomas F. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Thomas F. - Life Before In-Office BPH Therapy	9/7/2012
Paul H. - Life After In-Office BPH Therapy	9/7/2012
Paul H. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Paul H. - Life Before In-Office BPH Therapy	9/7/2012

Video Name	Release Date
Hubert W. - Life After In-Office BPH Therapy	9/7/2012
Hubert W. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Hubert W. - Life Before In-Office BPH Therapy	9/7/2012
Urologix: In-Office Therapy Comprehensive Overview	4/22/2012
Urologix: Our Story	4/14/2012
Patient Education Seminar	4/14/2012
Urologix: Your Trusted Partner	8/13/2012
Prostiva® RF Therapy: Technology Overview	7/20/2012
Cooled ThermoTherapy™: Technology Overview	7/20/2012
Urologix Prostiva and Cooled ThermoTherapy Patient Selection Overview	7/20/2012
Fact, Not Fiction: The Truth about In-Office BPH Procedures	6/22/2012

Urologix, Inc. claims copyrights on all printed advertisements.

VOLUNTARY SURRENDER AGREEMENT

This Voluntary Surrender Agreement (this "Agreement") has been executed as of January 29, 2016, by and between UROLOGIX, INC., a Minnesota corporation ("Debtor"), and MEDTRONIC, INC., a Minnesota corporation ("Creditor").

RECITALS

A. Debtor, Creditor and Medtronic VidaMed, Inc., a Delaware corporation ("VidaMed"), are parties to that certain Restructuring Agreement and Amendment to Transaction Documents dated as of June 28, 2013, pursuant to which, among other things, Debtor issued to Creditor a Promissory Note of even date therewith in the original principal amount of \$5,332,537.72 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Note").

B. Debtor and Creditor are also parties to that certain Security Agreement dated as of June 28, 2013, as amended by that certain Forbearance Agreement and Amendment to Security Agreement dated as of December 8, 2015 by and among Debtor, Creditor and Vidamed, as amended by that certain First Amendment to Forbearance Agreement and Amendment to Security Agreement dated December 30, 2015 and as further amended by that certain Second Amendment to Forbearance Agreement and Amendment to Security Agreement dated January 19, 2016 (as so amended, the "Forbearance Agreement") (as amended, and as the same may be further amended, restated, supplemented or otherwise modified from time to time the "Security Agreement") pursuant to which, among other things, Debtor granted to Creditor a security interest in all personal property and fixtures of Debtor (collectively, the "Collateral") as security for Debtor's obligations in favor of Creditor under the Note.

C. Debtor is justly indebted to Creditor under the terms of the Note.

D. Creditor's interest in the Collateral was and is duly perfected by the filing of a certain UCC1 financing statement with the Minnesota Secretary of State:

<u>Debtor</u>	<u>Date</u>	<u>File No.</u>
Urologix, Inc.	June 28, 2013	201332939103

E. Substantially all of the tangible portion of the Collateral is presently located at the following address (the "Premises"):

14405 21st Ave N #110
Minneapolis, MN 55447

F. As a result of the occurrence and the continuance of the Existing Defaults (as defined in the Forbearance Agreement), Creditor is entitled to, among other things, exercise its rights and remedies in respect of the Collateral in accordance with the terms of the Security Agreement and under applicable law.

G. Debtor has agreed to voluntarily surrender the Collateral other than the Carve-Out Collateral as defined in Section 3 below to Creditor for foreclosure in accordance with Article 9 of the Uniform Commercial Code (as in effect from time to time in the state of Minnesota, including without limitation, any amendments thereto which are effective after the date hereof and any successor statute(s), the "UCC"), subject to the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the premises herein set forth and for other good and valuable good consideration, the nature, receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

AGREEMENT

1. Recitals and capitalized terms. The foregoing recitals are incorporated herein by reference and constitute a part of this Agreement for all purposes. Capitalized terms shall have the meaning defined in this Agreement or in the Forbearance Agreement, unless the context requires otherwise.

2. Surrender of Collateral, Proceeds and Records. Debtor hereby surrenders the Collateral other than the Carve-Out Collateral to Creditor for such disposition as Creditor may select in accordance with the UCC and any other applicable law, under such terms as Creditor may agree. Debtor hereby further surrenders and relinquishes to Creditor the possession and right to possession of all proceeds and products of the Collateral other than the Carve-Out Collateral. In addition, upon execution of this Agreement and from time to time thereafter, Debtor shall deliver to Creditor such books, records, documents or other information together with such additional instruments or documents as Creditor may reasonably request, and, upon reasonable notice shall afford to the officers and authorized representatives of Creditor free access to the offices, books, and records of Debtor in order that Creditor may have full opportunity to make such investigation as it desires relating to the Collateral or the proceeds therefrom. The surrender of the Collateral other than the Carve-Out Collateral by Debtor hereunder is intended to be, and shall constitute, a voluntary surrender of the same in connection with Creditor's foreclosure of its liens on and security interests in such Collateral only. THE SURRENDER EFFECTED HEREUNDER IS NOT A TRANSFER FOR SECURITY, NOR IS IT INTENDED TO CONSTITUTE A RETENTION OF ANY COLLATERAL IN SATISFACTION OF ALL OR ANY PORTION OF THE OBLIGATIONS OF DEBTOR UNDER THE NOTE OR ANY OTHER OPERATIVE DOCUMENT (AS DEFINED IN THE FORBEARANCE AGREEMENT) (COLLECTIVELY, THE "OBLIGATIONS").

3. Carve-Out Collateral. Debtor is not surrendering or waiving any rights under this Agreement or otherwise with respect to (i) any cash and cash equivalents on hand or on deposit as of the date hereof, or any deposit or similar accounts in which Debtor deposits cash, but, for the avoidance of doubt, expressly excluding any cash, cash equivalents or other proceeds (or rights in respect thereof) now or hereafter obtained by Debtor in respect of any accounts receivables of Debtor outstanding as of the date hereof and (ii) the assets of Debtor described on Exhibit A hereto (collectively, the "Carve-Out Collateral"). Subject to Section 8(c) hereof, (i) Creditor hereby authorizes and consents to Debtor's collection, retention, use and disposition of the Carve-Out Collateral solely in accordance with Exhibit B hereto and (ii) Debtor hereby agrees to collect, retain, use and dispose of the Carve-Out Collateral solely in accordance with Exhibit B hereto.

4. Access to Premises/Books and Records. Debtor agrees that at any time upon reasonable notice, Creditor, and its agents or representatives, may enter the Premises for the purpose of preparing the Collateral other than the Carve-Out Collateral for sale or other disposition and for purposes of conducting a foreclosure sale of such Collateral in accordance with the UCC. Debtor further agrees that at any time Creditor may sell, lease or license the Collateral surrendered pursuant to this Agreement privately or conduct a public auction of such Collateral at the Premises at any time designated by Creditor or its auctioneer and that Creditor and its auctioneer (in the case of public disposition) shall provide such notice as may be required under the UCC. Debtor agrees to provide reasonable access to the Premises to any party wishing to inspect the Collateral prior to any such sale. Debtor shall not be entitled to any compensation by Creditor for the use of the Premises under this Agreement.

5. Location of Collateral. Debtor shall at all times maintain all equipment and other tangible Collateral solely at the Premises and shall not remove such Collateral from the Premises without Creditor's prior written consent except as may be expressly permitted under the Security Agreement. Debtor shall not, without the prior written consent of Creditor, sell, transfer or otherwise dispose of any of the Collateral except as may be expressly permitted under the Security Agreement or this Agreement.

6. Nonassumption. Debtor agrees that (a) Creditor shall not be liable to Debtor or any other party as a result of any of the activities described in this Agreement, and (b) by taking possession of the Collateral surrendered pursuant to this Agreement, Creditor does not intend to create any third party beneficiary rights in any third party and does not undertake or assume any obligations of Debtor to any such third party. It is understood and agreed that in connection with this Agreement and Creditor's rights hereunder Creditor has not assumed any of Debtor's obligations with respect to the Premises, including, but not limited to, any obligations to pay rent, to pay utilities, to pay taxes, to maintain the Premises in the proper state of repair or to insure the Premises against loss. Under no circumstances shall Creditor, or any of its agents, be deemed a mortgagee-in-possession, agent, representative or "responsible party" of Debtor for any purpose.

7. Reasonable Care of Collateral. It is agreed that Creditor will be deemed to have exercised reasonable care in the possession of the Collateral if it maintains the tangible Collateral at the Premises, it being understood, however, that Creditor shall have the right to move such Collateral to any location of its choice, whether before or after the date of the sale of the Collateral surrendered pursuant to this Agreement.

8. Disposition of Collateral.

(a) Creditor may proceed to dispose of the Collateral other than the Carve-Out Collateral by private sale, public auction or in a manner contemplated under this Agreement or in any other manner permitted under the Security Agreement, the UCC or applicable law.

(b) DEBTOR HEREBY WAIVES ALL NOTICES OF DEFAULT OR DISPOSITION OF THE COLLATERAL OTHER THAN THE CARVE-OUT COLLATERAL AS MAY BE REQUIRED BY THE SECURITY AGREEMENT, UCC OR THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE NOW IN EFFECT IN ANY OTHER STATES HAVING JURISDICTION OVER THE DISPOSITION OF THE COLLATERAL. DEBTOR HEREBY WAIVES ALL NOTICES OF DEFAULT OR DISPOSITION AS MAY BE REQUIRED BY THE SECURITY AGREEMENT, UCC OR THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE NOW IN EFFECT IN ANY OTHER STATES HAVING JURISDICTION OVER THE DISPOSITION OF THE COLLATERAL. Debtor specifically waives after default, any right to receive notice prior to the disposition of the Collateral subject to this Agreement under Section 9-611 of the UCC, and any right to redeem such Collateral prior to sale. Except as specifically set forth herein, Debtor hereby renounces all rights in or relating to the Collateral subject to surrender in this Agreement under the UCC (including, without limitation, Sections 9-609 through 9-624) or under the provisions of the Uniform Commercial Code now in effect in any other state having jurisdiction over the disposition of the Collateral other than the Carve-Out Collateral, and specifically authorizes the surrender and relinquishment of such Collateral to Creditor.

(c) Without in any manner limiting Creditor's rights as set forth in the Security Agreement or any other Operative Document, Creditor shall have the right and authority to collect for the account of Debtor, but for the exclusive benefit of Creditor, all accounts receivable, notes receivable and other items of Collateral subject to surrender under this Agreement which shall be transferred to Creditor, as provided herein, and to indorse with the name of Debtor any checks or other items hereafter received

on account of such receivables or other items. Debtor shall hold in trust for, and promptly transfer and deliver to, Creditor, or its designees or assigns, any cash or other property that Debtor may receive in respect of such accounts receivable or other items, and shall refrain from depositing payments received by Debtor from the disposition of Collateral (other than Carve-Out Collateral) in any account other than an account designated by Creditor. If the Carve-Out Collateral is not fully exhausted as of April 30, 2016 through the disposition thereof by Debtor in accordance with Section 3 hereof, Debtor agrees to promptly deliver all then remaining Carve-Out Collateral to Purchaser. All payments made to Creditor and Purchaser pursuant to this Section 8(c) shall be made in accordance with payment instructions delivered by Creditor and Purchaser, respectively, to Debtor in writing.

(d) The proceeds of the sale or other disposition of the Collateral shall be applied by Creditor in accordance with the provisions of the Security Agreement and the Note.

(e) Debtor hereby acknowledges and agrees that the Collateral has not been taken by Creditor in satisfaction of the Obligations and that nothing contained herein shall be construed as a waiver of any claim of Creditor against Debtor or as a release or discharge of any indebtedness owed by Debtor under the Note or any other Operative Document. Debtor specifically agrees that Debtor shall be liable for all sums remaining due in respect of the Obligations after application of the proceeds of sale or other disposition of the Collateral.

(f) Debtor agrees that the disposition of Collateral contemplated under this Agreement represents a commercially reasonable disposition of Collateral.

(g) Debtor hereby acknowledges and agrees to refrain from transferring, concealing, destroying, altering or taking any action with regard to Debtor's books and records, whether hard copy or stored electronically.

(h) Debtor hereby (i) acknowledges and agrees that the execution and delivery of this Agreement is conclusive of the fact that there has not been, and that there will not be, an occurrence of any event that constitutes an "Unwind Event" within the meaning of the Forbearance Agreement, and that Section 11 of the Forbearance is hereby terminated and of no further force or effect and (ii) waives any and all rights to assert or claim the occurrence of an Unwind Event. Debtor does not, and hereby covenants that it will not, contest that Creditor has and will continue to possess valid and perfected security interests in, and liens upon, all of the Collateral surrendered pursuant to this Agreement.

9. Consent Matters.

(a) To the extent that the assignment of any contract, license, lease, commitment, or receivable to be assigned to Creditor shall require the consent of any other party to such contract, license, lease, commitment, or receivable, upon Creditor's request, Debtor shall use its reasonable best efforts to obtain forthwith the consent of the other party to such contract, license, lease, commitment, or receivable to the assignment thereof to Creditor or any assignee thereof.

(b) Real Property Lease. In the event that Creditor or any assignee or transferee of Creditor including but not limited to the purchaser of a public or private sale conducted pursuant to Article 9 of the UCC ("Transferee") seeks to lease the real property occupied by Debtor, Debtor will cooperate with Creditor or Transferee in negotiating an assumption of the existing lease or terminating the existing lease in connection with entering into a new lease with Creditor or Transferee. Upon the request of Creditor or Transferee, Debtor will vacate the leased premises.

(c) Debtor consents: (i) to the disposition of the Collateral (other than Carve-Out Collateral) pursuant to a private sale under Article 9 of the Uniform Commercial Code (as enacted in Minnesota) to Project Trojan IP Acquisition LLC and Project Trojan Acquisition LLC (collectively, "Purchaser") pursuant to the terms of that certain Secured Party Sale Agreement of even date herewith; and (ii) to the assignment to the Purchaser of the Creditor's rights under this Surrender Agreement to enforce any payment obligations that Debtor may owe to the "Purchaser" as that term is defined in the Forbearance Agreement which the Debtor acknowledges the Purchaser shall have the right to enforce.

10. Termination of Forbearance. Pursuant to the terms of the Forbearance Agreement, Debtor agrees and acknowledges that the execution of this Agreement terminates the Forbearance Period (as that term is defined in the Forbearance Agreement) and that the date of this Agreement is the Termination Date as defined in the Forbearance Agreement.

11. Representations of Debtor. Debtor hereby represents and warrants to Creditor as follows:

(a) Debtor is a corporation duly organized and validly existing under the laws of the State of Minnesota.

(b) This Agreement has been approved by all necessary corporate action of Debtor and constitutes the legally valid, binding and fully enforceable obligation of Debtor.

(c) Debtor has duly filed or properly extended the filing dates for all required federal, state, county, and local tax reports and returns, and such reports and returns are true and correct in all material respects to the best of Debtor's knowledge. Debtor will file all such reports and returns when due in the future, and will provide copies of such reports and returns to Creditor upon request. Without limiting the generality of the foregoing, Debtor specifically represents and warrants to Creditor that Debtor has paid or will pay all employee wage claims and all withholding and social security and sales tax and medical device tax obligations of Debtor and all unemployment and worker's compensation premiums payable by Debtor.

(d) Debtor owns the Collateral free and clear of all liens and encumbrances (except for liens in favor of Creditor).

12. Release. Creditor hereby releases, remises, acquits and forever discharges any and all of Debtor's past and present officers and directors (all of the foregoing hereinafter called the "Debtor Released Parties"), from any and all actions and causes of action, judgments, executions, suits, debts, claims, demands, liabilities, obligations, damages and expenses of any and every character, known or unknown, direct and/or indirect, at law or in equity, of whatsoever kind or nature, for or because of any matter or things done, omitted or suffered to be done by any of the Debtor Released Parties prior to and including the date of execution hereof, and in any way directly or indirectly arising out of or in any way connected to this Agreement, the Collateral, the Note, the other Operative Documents or otherwise as part of their relationship with Debtor (collectively, "Losses"), provided, however, that such release, remise, acquittal and discharge shall be in all respects limited to Losses in excess of \$5,000,000 in the aggregate, and Creditor expressly retains all rights and remedies against the Debtor Released Parties under applicable law with respect to Losses not in excess of \$5,000,000 in the aggregate, and further provided that any claim by Creditor against any Debtor Released Parties in respect of Losses must be made in writing on or prior to the sixth anniversary of the date hereof or be barred, provided, further, that the provisions of this Section 12 shall be inapplicable and shall be of no force or effect with respect to any Losses arising from any fraudulent conduct, statement act or omission, or any act or omission constituting criminal conduct under applicable law, in each case by any Debtor Released Party. Creditor agrees not to commence or join any lawsuit or other legal or equitable action or proceeding in which any Debtor

Released Party is an adverse party and which involves any of the matters released hereby, subject to the limitations set forth herein. Nothing contained herein shall release, or operate to release, Debtor from any Obligations.

13. Miscellaneous.

(a) Survival of Representations. All representations and warranties of the parties hereunder shall survive the termination of this Agreement and the repayment of the Obligations.

(b) Notices. Notices to any party hereunder shall be sent in accordance with the Security Agreement.

(c) Agreement Jointly Drafted. The parties agree that this Agreement shall not be construed against any party to the Agreement on the grounds that such party drafted this Agreement, but shall be construed as if all parties jointly prepared this Agreement, and any uncertainty or ambiguity shall not on such grounds be interpreted against any one party.

(d) Advice of Counsel Obtained. Each of the parties acknowledges and represents that it has had the opportunity to consult with legal, financial, and other professional advisors as it deems appropriate in connection with its consideration and execution of this Agreement. Each undersigned party further represents and declares that in executing this Agreement, it has relied solely upon its own judgment, belief and knowledge, and the advice and recommendation of its own professional advisors, concerning the nature, extent and duration of its rights, obligations and claims; that it has reviewed its records, evaluated its position and conducted due diligence with regard to all rights, claims or causes of action whatsoever with respect to any and all other parties; and that it has not been influenced to any extent whatsoever in executing this Agreement by any representations or statements made by the other party or its representatives, except those expressly contained herein.

(e) Entire Agreement; Alteration or Amendment. This Agreement embodies the entire agreement between the parties and may not be altered or amended except by a writing signed by the parties.

(f) Conflicts with Operative Documents. To the extent that the rights of Creditor or the obligations of Debtor as set forth in this Agreement differ from, are in consistent with or conflict with those set forth in the Security Agreement, the Forbearance Agreement or any other Operative Document, the provisions herein shall control.

(g) Captions. The captions are for convenience of the parties only and shall not control or affect the meaning or construction of any provision of this Agreement.

(h) Counterparts; Facsimile. This Agreement may be executed in one or more counterparts (including electronic counterparts), each of which shall be an original, but all of which taken together shall constitute one and the same instrument. Execution of this Agreement by delivery of an electronic copy of a signature page shall be binding on the party transmitting its signature by such method, and shall be deemed to have the same force and effect as an original signature.

(i) Non-waiver. No delay or failure by a party to exercise any right under this Agreement or any of the Loan Documents, and no partial or single exercise of that right, shall constitute a waiver of that or any other right, unless otherwise expressly provided herein.

(j) Governing Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Minnesota, without giving effect to conflict of law principles thereof.


(k) Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors, and assigns.

[Remainder of page intentionally blank; signature page follows]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date and year first above written.

DEBTOR:

UROLOGIX, INC.,
a Minnesota corporation

By: 
Name: Gary R. Lind
Title: CEO

CREDITOR:

MEDTRONIC, INC.,
a Minnesota corporation

By: _____
Name: _____
Title: _____

[Signature Page to Voluntary Surrender Agreement]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date and year first above written.


DEBTOR:

UROLOGIX INC.,
a Minnesota corporation

By: _____
Name: _____
Title: _____

CREDITOR:

MEDTRONIC, INC.,
a Minnesota corporation

By:  _____
Name: Tom Tefft
Title: Senior Vice President

[Signature Page to Voluntary Surrender Agreement]

Exhibit A
Assets of Debtor Constituting Carve-Out Collateral

<u>Category of Carve-Out Collateral</u>	<u>Available Balance</u> <u>as of 1/29/16</u>
Restricted Cash	\$40,000
Director & Officer Ins. Credit	\$26,667
Excess D&O Credit	\$20,847
Emp Prac liab Credit	\$4,315
Fiduciary Credit	\$0
Com. Package inc Auto Credit	\$5,194
Work Comp Credit	\$1,851
Umbrella Credit	\$508
Crime Credit	\$591
Foreign Package Ins. Credit	\$850
Subtotal potential insurance credits	\$60,823
Total	\$100,823

Exhibit B
Disposition of the Carve-Out Collateral

As used in this Exhibit B, the term “Closing Date” means the date of the Voluntary Surrender Agreement to which this Exhibit B is attached and “Urologix” means Debtor. Other capitalized terms shall have the meanings ascribed to them in the Voluntary Surrender Agreement.

A. Urologix shall use the Carve-Out Collateral to pay the “Critical Obligations” which are as follows:

Category	Estimate of Net Cash at Closing (1/29/2016) Required to Satisfy (\$408,712)
Accrued payroll & benefits	71,679
Accrued Vacation (including 7.65% payroll taxes)	142,951
Non-Hired Employee Liabilities	8,248
21st North Wind Down Expenses	15,000
D&O, EPL & Fiduciary Insurance Tails	25,700
Accrued Sales Tax	30,000
PWB FY16 Stub Tax Return Preparation Fees: Fed & State	14,000
Final state income tax payments for FY16 stub	9,305
Final credit card payment	13,500
L&V Legal Fees – Transaction	14,000
401(k) Transfer/Admin Fees	1,503
Fees to produce ULGX W-2s, 1099's, etc. (CY16)	1,600
Dissolution & shareholder communication (Broadridge)	12,363
Wells Fargo shareholder services shut down	5,541
Accrued Commissions for January Sales	30,000
Accrued Travel Expense	6,952
California Unemployment Deficiency	6,370

In the case of each Critical Obligation, Urologix will pay no more than the contractually or legally obligated amount, but may pay such amount when due or earlier in its discretion; provided that Urologix shall in no event pay more than \$15,000 in respect of 21st North Wind Down Expenses.

In addition, Urologix shall use the Carve-Out Collateral to make a payment on the Closing Date in settlement to Carabiner relating to that certain letter agreement dated November 14, 2014 with Urologix, in the amount of \$60,000.

B. In addition, Urologix shall be entitled to use the Carve-Out Collateral in the following order of priority: (i) first, to pay or make provision for the full amount of the actual Critical Obligations in accordance with Section A; and (ii) second, to pay the following in any order of priority: (1) an amount in settlement of certain obligations to Medmarc, up to a maximum of \$25,000 or such lesser amount as may be negotiated with Medmarc; and (2) any obligation or liability of Urologix (other than any Final Trade

Payable, as defined in Schedule III of the Forbearance Agreement, or any Critical Obligation) for which any director or officer of Urologix may be personally liable, or any lesser amount in settlement thereof.

C. Purchaser shall be entitled to such written reports regarding the use of the Carve-Out Collateral as it may reasonably request from time to time on and following the Closing Date.

ASSIGNMENT OF INTELLECTUAL PROPERTY

THIS ASSIGNMENT OF INTELLECTUAL PROPERTY (this "Assignment") is entered into as of January 29, 2016 by and between Project Trojan IP Acquisition LLC, a Delaware limited liability company ("Assignee"), and Medtronic, Inc., a Minnesota corporation (the "Assignor").

WHEREAS, the Assignee, the Assignor, and Project Trojan Acquisition LLC, a Delaware limited liability company, are parties to that certain Secured Party Sale Agreement (the "Purchase Agreement") as of even date herewith, pursuant to which the Assignor agreed to sell, and the Purchasers (as defined in the Purchase Agreement) agreed to purchase, certain assets of Urologix, Inc., a Minnesota corporation;

WHEREAS, pursuant to the Purchase Agreement, the Assignee has purchased all of the Assignor's right, title and interest in, to and under the intellectual property described on Exhibit A attached hereto (the "Transferred Intellectual Property"); and

WHEREAS, this Assignment of Intellectual Property is being delivered pursuant to the **Section 6.01(c)(vi)** of the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants set forth in the Purchase Agreement and hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties do hereby agree as follows:

1. Definitions. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Purchase Agreement.

2. Sale and Assignment of Transferred Intellectual Property. Effective on the date hereof, and upon the terms and subject to the conditions of the Purchase Agreement, the Assignor hereby sells, assigns, transfers, conveys and delivers to the Assignee, free and clear of all liens or encumbrances, all of Assignor's right, title, and/or interest in, to and under all of the Transferred Intellectual Property including all good will of the business symbolized thereby and including, without limitation, all issuances, registrations, applications, reissues, re-examinations, substitutions, and extensions thereof and all benefits, privileges, causes of action and remedies relating thereto throughout the world, including, without limitation, all of such Assignor's rights to: (a) apply for and maintain all registrations, renewals and/or extensions thereof; (b) claim priority under United States law or international convention; (c) bring actions and recover damages for past, present and future infringement or other violation thereof; and (d) grant licenses or other interests therein; provided, however, that this Assignment shall not constitute an assignment to the extent that, if it were to sell, convey, assign or transfer an interest in and to the Transferred Intellectual Property, it would impair the subsequent lawful and effective execution and recordation of a necessary country-specific form of assignment. The conveyance herein also includes any further inventions relating to the patent applications included in the Transferred Intellectual Property or any other patent applications based exclusively on the Transferred Intellectual Property.

3. No Modification; Purchase Agreement. The Assignor, by its execution of this Assignment, and the Assignee, by its acceptance of this Assignment, hereby acknowledges and agrees that neither the representations and warranties nor the rights, remedies or obligations of any party under the Purchase Agreement shall be deemed to be enlarged, modified or altered in any way by this Assignment. In the event of a conflict between the terms and provisions of this Assignment and the Purchase Agreement, the terms and provisions of the Purchase Agreement shall govern and control.

4. Recordation of Assignment of Transferred Intellectual Property. The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any other applicable governmental office, agency or registrar (including the patent, copyright and/or trademark office or agency of all applicable foreign countries), (a) to issue any and all issuances, registrations or applications therefor included in the Transferred Intellectual Property to the Assignee as the assignee and owner of the Assignor's entire right, title, and/or interest in, to and under such issuances, registrations or applications therefor and (b) to record the Assignee as the assignee and owner of Transferred Intellectual Property.

5. Undertaking. The Assignor acknowledges and agrees that it shall not execute any instrument that conflicts with the terms of this Assignment.

6. Further Assurances. The Assignor shall provide Assignee and its successors and assigns reasonable cooperation and assistance at Assignee's request and expense (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation as may be reasonably required) as are reasonably requested by Assignee to effect, register or maintain the rights assigned herein, including: (a) the preparation and prosecution by Assignee of any applications or registrations assigned herein; and (b) the prosecution or defense by Assignee of any interference, opposition, reexamination, reissue, *inter partes* review, post grant proceeding, infringement or other proceeding that may arise in connection with any of the rights assigned herein, including, without limitation, testifying as to the fact of the assignment of rights hereunder.

7. Governing Law. This Assignment and the legal relations among the parties hereto will be governed by and construed in accordance with the internal substantive laws of the State of Minnesota (without regard to the laws of conflict that might otherwise apply) as to all matters, including matters of validity, construction, effect, performance and remedies.

8. Successors and Assigns. This Assignment shall be binding upon and inure to the benefit of the parties hereto and to their respective successors and assigns.

9. Counterparts. This Assignment may be executed in two counterparts, each of which shall be deemed an original, but both of which shall constitute one and the same instrument.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed and delivered as of the date first above written.

ASSIGNEE:

PROJECT TROJAN IP ACQUISITION LLC

By: Bryon Merade

Name: Bryon Merade

Title: Chief Executive Officer

ASSIGNOR:

MEDTRONIC, INC.

By: _____

Name: Tom Tefft

Title: Senior Vice President

[Signature Page to Intellectual Property Assignment]

TRADEMARK
REEL: 005857 FRAME: 0763

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed and delivered as of the date first above written.

ASSIGNEE:

PROJECT TROJAN IP ACQUISITION LLC

By: _____

Name:

Title:

ASSIGNOR:

MEDTRONIC, INC.

By:  _____

Name: Tom Tefft

Title: Senior Vice President

[Signature Page to Intellectual Property Assignment]

Exhibit A

Transferred Intellectual Property

[See Attachment]

Urologix, Inc.
Intellectual Property Rights
November 23, 2015

(a) Registered Trademarks:

TRADEMARK	FILED	APPL#	REG DATE	REG#	STATUS
COOLWAVE UNITED STATES	4/1/2004	78/394,674	8/7/2007	3,276,185	REGISTERED
CYC ADVANCE UNITED STATES	10/24/2007	77/311,966	1/6/2009	3,558,641	REGISTERED
PROSTATRON UNITED STATES	5/22/1989	73/801,253	11/20/2000	1,623,355	REGISTERED
TARGIS UNITED STATES	9/4/1997	75/351,846	11/6/2001	2,504,853	REGISTERED
UROLOGIX CANADA	9/9/1994	763,755	11/24/1995	TMA450,772	REGISTERED
FRANCE	9/8/1994	8835	9/8/1994	94/535923	REGISTERED
JAPAN	4/5/1994	33544/94	5/23/1997	3312380	REGISTERED
UNITED STATES	4/2/1992	74/261,868	9/7/1993	1,792,148	REGISTERED
UROLOGIX CIRCLE LOGO UNITED STATES	7/31/1995	74/708,152	4/1/1997	2,049,865	REGISTERED
TUMT UNITED STATES	11/9/1989	73/838,022	12/25/1990	1,628,985	REGISTERED

Other OUS Trademarks (Abandoned):

UROLOGIX	SE	UROLOGIX AB	2009-04925	24-Jun-2009
PROSTATRON	FR	UROLOGIX, INC.	1501018	30-Nov-1988
PROSTATRON	CH	UROLOGIX, INC.	CHTM.062662001	2001-06-25
TUMT	CH	UROLOGIX, INC.	CHTM.062672001	2001-06-25
UROLOGIX	DE	Urologix, Inc.	DETM.DE2907441	1994-09-06
PROSTATRON	SG	UROLOGIX, INC.	SGTM.T9110781I	1991-12-06

Non-registered Trademarks:

Cooled ThermoTherapy
 Prostateprobe

Website Domains:

Domain Name	Registered with:	Expires on:
Urologixmobile.com	godaddy.com	8/6/2016

Domain Name	Registered with:	Expires on:
Helpmyprostate.com	godaddy.com	10/29/2017
CTTvideo.com	godaddy.com	4/26/2018
Prostivavideo.com	godaddy.com	4/26/2018
beat-bph.com	Networksolutions.com	5/24/2016
beatbph.com	Networksolutions.com	3/28/2018
bphreatment.com	Networksolutions.com	6/19/2016
cooledmicrowavethermotherapy.com	Networksolutions.com	10/12/2020
cooledthermotherapy.com	Networksolutions.com	10/12/2020
getoffyourmeds.com	Networksolutions.com	9/7/2017
getoutofthebathroom.com	Networksolutions.com	9/7/2017
prostiva.com	Networksolutions.com	8/1/2016
takecontrolofyourflow.com	Networksolutions.com	8/27/2018
targis.com	Networksolutions.com	9/2/2016
urologix.com	Networksolutions.com	7/28/2016
urologixcertificates.com	Networksolutions.com	7/24/2018
vidamed.com	Networksolutions.com	11/16/2017
beat-bph.com	Networksolutions.com	5/24/2016

(b) Copyrights:

The following video clips are copyrighted by Urologix, Inc.:

Video Title	Release Date
InView Segment	4/5/2014
Real Patients Talk About BPH and Cooled ThermoTherapy™ Treatment HD	10/31/2013
Procedure Overview: Modified Periprostatic Nerve Block (with J. Randolph Behrs M.D., F.A.C.S.)	10/8/2013
FAQ: What is the potential impact on my sexual function?	7/25/2013
FAQ: What are the long term outcomes?	7/25/2013
FAQ: What are the treatment options?	7/25/2013
FAQ: What are the long term risks?	7/25/2013
FAQ: IS BPH life threatening?	7/25/2013
FAQ: What is BPH?	7/25/2013
CTT Animation	7/15/2013
Prostiva Animation	7/15/2013
The Prostiva® Procedure: Mark And Shelly's Story	6/11/2013
The Balancing Act Segment	6/4/2013
Dr. Craig Smith: Patient 1 (3-5-2013) Prostiva® Procedure	6/4/2013
Dr. Craig Smith: Patient 4 (3-5-2013) Prostate Block	6/4/2013
Dr. Craig Smith: Patient 4 (3-5-2013) Prostiva® Procedure	6/4/2013
Dr. Craig Smith: Patient 3 (3-5-2013) Prostiva® Procedure	6/4/2013
Dr. Craig Smith: Patient 3 (3-5-2013) Prostate Block	6/4/2013

Document Title	Issue Date
Hubert W. - Life Before In-Office BPH Therapy	9/7/2012
Urologix: In-Office Therapy Comprehensive Overview	4/22/2012
Urologix: Our Story	4/14/2012
Patient Education Seminar	4/14/2012
Urologix: Your Trusted Partner	8/13/2012
Prostiva® RF Therapy: Technology Overview	7/20/2012
Cooled ThermoTherapy™: Technology Overview	7/20/2012
Urologix Prostiva and Cooled ThermoTherapy Patient Selection Overview	7/20/2012
Fact, Not Fiction: The Truth about In-Office BPH Procedures	6/22/2012

Urologix, Inc. claims copyrights on all printed advertisements.

(c) Issued Patents:

US ISSUED PATENTS

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ¹
U510.114.101 (U43.12-0001)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (U43.13-0001) (U43.13-0002)	03/06/92	05/09/95	5,413,588*
U510.162.101 (U43.12-002)	METHOD FOR TREATING INTERSTITIAL TISSUE ASSOCIATED WITH MICROWAVE THERMAL THERAPY	03/06/92	07/19/94	5,330,518*
U510.115.101 (U43.12-0003)	GAMMA MATCHED HELICAL DIPOLE MICROWAVE ANTENNA (U43.13-0003) (U43.13-0004)	03/06/92	04/05/94	5,300,099*
U510.112.101 (U43.12-0006)	BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING (U43.13-0005)	07/09/93	11/07/95	5,464,437*
U510.113.101 (U43.12-0008)	GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA WITH TUBULAR-SHAPED CAPACITOR (U43.13-0007)	09/17/93	12/06/94	5,370,677*
U510.109.101 (U43.12-0010)	COOLANT PRE-CHILLING PRIOR TO BENIGN PROSTATIC HYPERPLASIA TREATMENT (Continuation-in-Part of U43.12-0001)	09/20/94	04/15/97	5,620,480*

¹ Expired indicated by *

Video Title	Release Date
Dr. Craig Smith: Patient 2 (3-5-2013) Prostate Block	6/4/2013
Dr. Craig Smith: Patient 1 (3-5-2013) Prostate Block	6/4/2013
Dr. Randy Beahrs: Patient (3-26-2013) Prostate Block	6/4/2013
SESAUA March 2013 Conference Symposium	4/5/2013
Roland W. - After Having In-Office BPH Therapy	4/4/2013
Roland W. - Discusses His In-Office BPH Procedure	4/4/2013
Roland W. - Before Having In-Office BPH Therapy	4/4/2013
Doug K. - After Having In-Office BPH Therapy	4/4/2013
Doug K. - Discusses His In-Office BPH Procedure	4/4/2013
Doug K. - Before Having In-Office BPH Therapy	4/4/2013
Dean N. - After Having In-Office BPH Therapy	4/4/2013
Dean N. - Discusses His In-Office BPH Procedure	4/4/2013
Dean N. - Before Having In-Office BPH Therapy	4/4/2013
Bill K. - After Having In-Office BPH Therapy	4/4/2013
Bill K. - Discusses His In-Office BPH Procedure	4/4/2013
Bill K. - Before Having In-Office BPH Therapy	4/4/2013
Cooled ThermoTherapy Patient Education	3/22/2013
Prostiva® RF Therapy Patient Education	12/21/2012
Explore In-Office BPH Therapy	9/17/2012
About Benign Prostatic Hyperplasia	9/17/2012
Prostiva® RF Therapy Procedure	9/11/2012
Cooled ThermoTherapy™ Procedure	9/11/2012
Patients' Perspectives: Having In-Office BPH Therapy	9/7/2012
Paul A. - Life After In-Office BPH Therapy	9/7/2012
Paul A. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Paul A. - Life Before In-Office BPH Therapy	9/7/2012
John H. - Life After In-Office BPH Therapy	9/7/2012
John H. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
John H. - Life Before In-Office BPH Therapy	9/7/2012
Eric J. - Life After In-Office BPH Therapy	9/7/2012
Eric J. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Eric J. - Life Before In-Office BPH Therapy	9/7/2012
Thomas F. - Life After In-Office BPH Therapy	9/7/2012
Thomas F. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Thomas F. - Life Before In-Office BPH Therapy	9/7/2012
Paul H. - Life After In-Office BPH Therapy	9/7/2012
Paul H. - Discusses His In-Office BPH Therapy Procedure	9/7/2012
Paul H. - Life Before In-Office BPH Therapy	9/7/2012
Hubert W. - Life After In-Office BPH Therapy	9/7/2012
Hubert W. - Discusses His In-Office BPH Therapy Procedure	9/7/2012

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ¹
U510.110.101 (U43.12-0010)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (Continuation of U43.12-0001, filed 3-6-92)	03/09/94	11/07/95	5,464,445*
U510.102.101 (U43.12-0014)	METHOD OF PRODUCING DEPTH OF COAGULATION NECROSIS	06/26/95	12/01/98	5,843,144*
U510.111.101 (U43.12-0016)	DEVICE AND METHOD FOR PREVENTING RESTENOSIS	05/06/97	04/24/01	6,223,085*
(U43.12-0017)	DEVICE FOR TRANSURETHRAL THERMAL THERAPY WITH COOLING BALLOON	06/17/96	09/01/98	5,800,486
U510.116.101 (U43.12-0019)	BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING (Continuation of U43.12-0006, filed 7/8/93)	05/23/95	11/01/96	5,575,811*
U510.117.101 (U43.12-0020)	BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING (Divisional of U43.12-0006, filed 7/8/93)	04/26/95	07/01/97	5,643,335*
U510.118.101 (U43.12-0021)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (Divisional of U43.12-0011, filed 3/6/92)	03/30/95	08/13/96	5,545,137*
U510.119.101 (U43.12-0022)	DEVICE FOR TRANSURETHRAL THERMAL THERAPY	06/06/95	05/13/97	5,628,770*
U510.121.101 (U43.12-0024)	MICROWAVE ANTENNA FOR ARTERIAL MICROWAVE APPLICATOR	06/17/96	07/07/98	5,776,176
U510.157.101 (U43.12-0025)	VOLTAGE CONTROLLED VARIABLE TUNING ANTENNA	03/26/96	08/17/99	5,938,692
U510.122.101 (U43.12-0026)	RECTAL THERMOSENSING UNIT	08/30/96	08/01/98	5,792,070
U510.124.101 (U43.12-0027)	LIQUID COOLANT SUPPLY SYSTEM	04/25/96	03/31/98	5,733,319
U510.125.101 (U43.12-0028)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (Divisional off first parent, filed 3/6/92) U43.12-0001, U43.12-0011, U43.12-0021)	07/19/96	05/26/98	5,755,754*

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ¹
U510.103.101 (U43.12-0030)	METHOD OF APPLYING MICROWAVE ENERGY WITH COOLING TO CARDIAC TISSUE (Divisional of U43.12-0015, filed 6/7/96)	12/20/96	01/19/99	5,861,021
U510.158.101 (U43.12-0031)	SYSTEM AND METHOD FOR TRANSURETHRAL HEATING WITH RECTAL COOLING	07/14/97	12/28/99	6,009,351
U510.159.101 (U43.12-0032)	METHOD OF AXIAL PREFERENTIAL THERMAL THERAPY (Divisional of U43.12-0029, filed 5/3/96)	03/24/97	05/04/99	5,899,932
U510.160.101 (U43.12-0033)	DEVICE AND METHOD FOR TREATMENT OF A PROSTATE WHILE PREVENTING URETHRAL CONSTRICTION DUE TO COLLAGEN RICH TISSUE SHRINKAGE	08/29/97	09/26/00	6,123,083
U510.161.101 (U43.12-0034)	AXIAL PREFERENTIAL THERMAL THERAPY (Divisional of U43.12-0029, filed 5/3/96)	03/03/97	11/16/99	5,987,360
U510.129.101 (U43.12-0035)	BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING (Continuation of U43.12-0020, filed 7/8/93)	06/23/97	08/03/99	5,931,860*
U510.130.101 (U43.12-0037)	LIQUID COOLANT SUPPLY SYSTEM (Divisional of U43.12-0027, filed 4/25/95)	07/14/97	12/28/99	6,007,571
U510.131.101 (U43.12-0038)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (Continuation of U43.12-0028, filed 3/6/92)	07/15/97	06/29/99	5,916,240*
U510.132.101 (U43.12-0039)	DEVICE FOR ASYMMETRICAL THERMAL THERAPY WITH HELICAL DIPOLE MICROWAVE ANTENNA (Divisional of U43.12-0028, filed 3/6/92)	07/30/97	06/29/99	5,916,241*
U510.133.101 (U43.12-0041)	RECTAL TEMPERATURE SENSING PROBE	4/7/2000	02/19/02	6,348,039
U510.134.101 (U43.12-0042)	MICROWAVE ENERGY DELIVERY SYSTEM INCLUDING HIGH PERFORMANCE DUAL DIRECTIONAL COUPLER FOR PRECISELY MEASURING FORWARD AND REVERSE MICROWAVE POWER DURING THERMAL THERAPY	11/5/98	05/23/00	6,067,475

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ¹
U510.135.101 (U43.12-0047)	VOLTAGE CONTROLLED VARIABLE TUNING ANTENNA (Divisional - U43.12-0025, filed 3/26/96)	10/22/97	02/29/00	6,032,078
U510.136.101 (U43.12-0048)	CANCER TREATMENT SYSTEM EMPLOYING SUPPLEMENTED THERMAL THERAPY	11/04/98	11/14/00	6,148,236
U510.137.101 (U43.12-0051)	DEVICE AND METHOD FOR INTRACAVITY CANCER TREATMENT	03/09/98	03/14/00	6,036,631
U510.138.101 (U43.12-0062)	THERMAL THERAPY CATHETER	04/30/99	12/12/00	6,161,049
U510.139.101 (U43.12-0063)	METHOD OF CONTROLLING THERMAL THERAPY	12/11/98	09/19/00	6,122,551
U510.140.101 (U43.12-0064)	THERMODYNAMIC MODELING OF TISSUE TREATMENT PROCEDURE	2/16/00	11/06/01	6,312,391
U510.141.101 (U43.12-0065)	DIRECTIONAL EMR CATHETER	04/03/02	05/25/04	6,740,108
U510.104.101 (U43.12-0069)	METHOD OF CONTROLLING THERMAL THERAPY (Continuation of U43.12-0063, filed 12/11/98)	04/20/00	12/03/02	6,490,488
U510.105.101 (U43.12-0070)	THERMAL THERAPY CATHETER (CIP of U43.12-0062, filed 4/30/99)	12/08/00	12/17/02	6,496,737
U510.107.101 (U43.12-0077)	RECTAL PROBE WITH DISPOSABLE BALLOON ASSEMBLY	3/28/05	04/02/13	8,409,109
U510.167.102	THERMAL THERAPY TEMPERATURE SENSOR CALIBRATION METHOD	4/27/09	10/30/12	8,301,264
U510.165.103	COOLED ANTENNA FOR DEVICE INSERTABLE INTO A BODY	4/9/10	5/20/14	8,728,068

FOREIGN PATENT GRANTS

DBC FILE NO.	TITLE	COUNTRY	PAT NO ²	GRANT DATE
U510.123.291 U43.13-0023	AXIAL PREFERENTIAL THERMAL THERAPY (U43.12-0029/32/34)	EPO: France, Germany and Great Britain	904030	08/13/08
U510.123.292 Continuation	AXIAL PREFERENTIAL THERMAL THERAPY	EP-Divisional	08 01 4293.8	
U510.123.311	AXIAL PREFERENTIAL THERMAL THERAPY (Based on PCT/US1997/007519)	FRANCE	904030*	08/13/08
U510.123.321	AXIAL PREFERENTIAL THERMAL THERAPY (Based on PCT/US1997/007519)	GERMANY	904030*	08/13/08
U510.123.322	AXIAL PREFERENTIAL THERMAL THERAPY (Based on EP, filed 5/2/97)	GERMANY	199745*	06/22/11
U510.123.751	AXIAL PREFERENTIAL THERMAL THERAPY (Based on PCT/US1997/007519)	GREAT BRITAIN	904030*	08/13/08
U510.123.752	AXIAL PREFERENTIAL THERMAL THERAPY (Based on EP, filed 5/2/97)	GREAT BRITAIN	1997455*	06/22/11
U510.142.321	DIPOLE MICROWAVE ANTENNA FOR ASYMMETRICAL THERMAL THERAPY (US Priority: U.S. Patent No. 5,413,588)	GERMANY	693 30947.4-08*	10/17/01
U510.142.751	DIPOLE MICROWAVE ANTENNA FOR ASYMMETRICAL THERMAL THERAPY (US Priority: U.S. Patent No. 5,413,588)	UNITED KINGDOM	762862*	12/10/99
U510.143.311	GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA (US Priority: U.S. Patent No. 5,843,114)	FRANCE	0634946*	03/01/93
U510.143.321	GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA (US Priority: U.S. Patent No. 5,843,114) (Based on PCT/US 1993/001780)	GERMANY	693 25797*	07/28/99

² Abandoned, expired or closed indicated by *

DBC FILE NO.	TITLE	COUNTRY	PAT NO ²	GRANT DATE
U510.143.751	GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA (US Priority: U.S. Patent No. 5,843,114) (Based on PCT/US1993/001780)	UNITED KINGDOM	0634946*	03/01/93
U510.144.311	BENIGN PROSTATIC HYPERPLASIA CATHETER (U.S. Priority: U.S. Patent No. 5,464,437) (Based on PCT/US1994/07352)	FRANCE	FR 707 502*	02/05/03
U510.144.321	BENIGN PROSTATIC HYPERPLASIA CATHETER (U.S. Priority: U.S. Patent No. 5,464,437) (Based on PCT/US1994/07352)	GERMANY	69432103.6-08*	02/05/03
U510.144.681	BENIGN PROSTATIC HYPERPLASIA CATHETER (U.S. Priority: U.S. Patent No. 5,464,437) (Based on PCT/US1994/07352)	SWEDEN	SE 707 502 (949220529)*	02/05/03
U510.144.751	BENIGN PROSTATIC HYPERPLASIA CATHETER (U.S. Priority: U.S. Patent No. 5,464,437) (Based on PCT/US1994/07352)	UNITED KINGDOM	0707502*	02/05/03
U510.147.291 U43.13-0049	(T3) DEVICE AND METHOD FOR PREVENTING RESTENOSIS (U43.12-0016)	EP	994670	08/21/13
U510.147.311	(T3) DEVICE AND METHOD FOR PREVENTING RESTENOSIS (U43.12-0016)	FRANCE	*	
U510.147.321	(T3) DEVICE AND METHOD FOR PREVENTING RESTENOSIS (U43.12-0016)	GERMANY	*	
U510.147.751	(T3) METHOD FOR PREVENTING RESTENOSIS (U43.12-0016)	UNITED KINGDOM	*	
U510.148.291 U43.13-0064	METHOD OF CONTROLLING THERMAL THERAPY	EP	1148837	9/26/12
U510.148.311 U43.13-0064	METHOD OF CONTROLLING THERMAL THERAPY (12-0063)	FRANCE	1148837*	9/26/12

OBC FILE NO.	TITLE	COUNTRY	PAT NO ²	GRANT DATE
U510.148.431 043-13-0064	METHOD OF CONTROLLING THERMAL THERAPY (12-0063)	ITALY	1148837*	9/26/12
U510.148.501 043.13-0064	METHOD OF CONTROLLING THERMAL THERAPY (12-0063)	NETHERLANDS	1148837*	9/26/12
U510.148.681 043.13-0064	METHOD OF CONTROLLING THERMAL THERAPY (12-0063)	SWEDEN	1148837	9/26/12
U510.148.691 U43.13-0064	METHOD OF CONTROLLING THERMAL THERAPY (12-0063)	SWITZERLAND	1148837*	9/26/12
U510.149.291	(Millennium)THERMAL THERAPY CATHETER (Based on PCT/US2000/007769)	EPO	1173108	07/20/2011
0510.149.151	(Millennium)THERMAL THERAPY CATHETER (Based on PCT/US2000/007769)	AUSTRIA	1173108	07/20/2011
U510.149.311	(Millennium)THERMAL THERAPY CATHETER (Based on PCT/US2000/007769)	FRANCE	1173108	07/20/2011
U510.149.321	(Millennium) THERMAL THERAPY CATHETER (Based on PCT/US2000/007769)	GERMANY	1173108	07/20/2011
U510.149.751	(Millennium)THERMAL THERAPY CATHETER (Based on PCT/US2000/007769)	UNITED KINGDOM	1173108	07/20/2011
U510.150.141 U43.13-0067	METHOD OF CONTROLLING THERMAL THERAPY (U.S. Priority: U.S. Patent No. 6,122,551) (Based on PCT/US1999/029381)	AUSTRALIA	762 862	10/23/03
U510.152.141 U43.13-0070	THERMAL THERAPY CATHETER (U.S. Priority: U.S. Patent No. 6,161,049) (Based on PCT/US2000/007769)	AUSTRALIA	762 886	10/23/03

Title	Publication number	Publication date	Inventor(s)	Applicant(s)	Application number	Priority number(s)
Arterial microwave applicator with cooling	AU3480697 (A)	1/7/1998	THOME SCOTT P. [US]; RUDIE ERIC N. [US]; DANN MITCHELL, [US]; HIROSE TERUO T. [US]	UROLOGIX INC. [US]	AU199700348060	US19960664363 19960617; WO1997US09975 19970610; US19960771214 19961220 US19970809007 19970303; US19970824064 19970324; WO1997US07519 19970502; US19960646746 19960503
Axial preferential thermal therapy	AU2826397 (A)	11/26/1997	MCGRATH JONATHAN R.; RUDIE ERIC N.; DANN MITCHELL REID JOHN M. [US]; KAUPHUSMAN JAMES V. [US]; PORTER CHRISTOPHER H. [US]; NEILSON BRUCE H. [US]	UROLOGIX INC	AU199700282630	WO1994US07352 19940629; US19930086901 19930708
BENIGN PROSTATIC HYPERPLASIA CATHETER WITH URETHRAL COOLING	EP0707502 (B1); EP0707502 (A4); EP0707502 (A1)	4/24/1996	REID JOHN M. [US]; KAUPHUSMAN JAMES V. [US]; PORTER CHRISTOPHER H. [US]; NEILSON BRUCE H. [US]	UROLOGIX INC. [US]	EP19940927052	US19930088901 19930708; WO1994US07352 19940629
BENIGN PROSTATIC HYPERPLASIA CATHETER WITH URETHRAL COOLING	AT232124 (T)	2/15/2003	DANN MITCHELL; THOME SCOTT P.; MCGRATH JONATHAN R.; RUDIE ERIC N.; FLACHMAN JONATHAN L.; HIROSE TERUO T FLACHMAN JONATHAN L. [US]; THOME SCOTT P. [US]; THOME SCOTT P. [US];	UROLOGIX INC. [US]	AT19940922052T	US19970853154 19970506; WO1998US07053 19980409
Device and method for preventing restenosis	AU6893698 (A)	11/27/1998	THOME SCOTT P. [US]; THOME SCOTT P. [US];	UROLOGIX INC.	AU199800689360	US19950469201 19950606 WO1996US07876 19960529; US19950469201 19950606 US19950466201 19950606; WO1996US07878 19960529
DEVICE FOR TRANSURETHRAL THERMAL THERAPY	CA2222202 (A1)	12/12/1996	THOME SCOTT P. [US]; THOME SCOTT P. [US];	UROLOGIX INC. [US]	CA19962222202	US19950469201 19950606 WO1996US07876 19960529; US19950469201 19950606 US19950466201 19950606; WO1996US07878 19960529
DEVICE FOR TRANSURETHRAL THERMAL THERAPY	EP0837715 (A1)	4/29/1998	THOME SCOTT P.; FLACHMAN JONATHAN L	UROLOGIX INC. [US]	EP19960916718	US19950469201 19950606 WO1996US07876 19960529; US19950469201 19950606 WO1996US07878 19960529
Device for transurethral thermal therapy with cooling balloon	AU710205 (B2)	9/16/1999	THOME SCOTT P.; FLACHMAN JONATHAN L	UROLOGIX INC	AU19960059385	US19950469201 19950606 WO1996US07876 19960529; US19950469201 19950606 WO1996US07878 19960529
Device for transurethral thermal therapy with cooling balloon	AU3284397 (A)	1/7/1998	THOME SCOTT P.; KAUPHUSMAN JAMES V.; DANN MITCHELL RUDIE ERIC N. [US]; NEILSON BRUCE H. [US]; KAUPHUSMAN JAMES V. [US]	UROLOGIX INC	AU199700328430	WO1997US08520 19970610; US19960672504 19960617 EP19930907679 19930301; US19920847716 19920306
Dipole microwave antenna for asymmetrical thermal therapy	EP1092452 (A3); EP1092452 (A2)	4/28/2001	RUDIE ERIC N. [US]; NEILSON BRUCE H. [US]; KAUPHUSMAN JAMES V. [US]	UROLOGIX INC. [US]	EP20010100744	EP19930907679 19930301; US19920847716 19920306
DIPOLE MICROWAVE ANTENNA FOR ASYMMETRICAL THERMAL THERAPY	AT206947 (T)	11/15/2001	RUDIE ERIC N. [US]; KAUPHUSMAN JAMES V. [US]; NEILSON BRUCE H. [US]	UROLOGIX INC. [US]	AT19930907079T	US19920847718 19920306; WO1993US01777 19930301

TRADEMARK

REEL: 005857 FRAME: 0776

Title	Publication number	Publication date	Inventor(s)	Applicant(s)	Application number	Priority number(s)
DIPOLE MICROWAVE ANTENNA FOR ASYMMETRICAL THERMAL THERAPY.	EP0632735 (B1); EP0632735 (A4); EP0632735 (A1)	1/11/1995	RUDIE ERIC N.[US]; KAUPHUSMAN JAMES V.[US]; NEILSON BRUCE H.[US]	UROLOGIX INC.[US]	EP19930907079	WO1993U501777 19930301; US19920847718 19920306
GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA	JPH07506741 (A)	7/27/1995			JP19930515793	US19920847915 19920306; WO1993U501780 19930301
GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA WITH TUBULAR-SHAPED CAPACITOR	CA2169338 (A1)	3/23/1995	RUDIE ERIC N.[US]; KLUGE STANLEY E.[US]	UROLOGIX INC.[US]	CA19940169338	US19930123321 19930917
GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA WITH TUBULAR-SHAPED CAPACITOR	EP0723468 (A4); EP0723468 (A1)	7/31/1996	RUDIE ERIC N.[US]; KLUGE STANLEY E.[US]	UROLOGIX INC.[US]	EP19940925856	WO1994U509145 19940812; US19930123321 19930917
GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA WITH TUBULAR-SHAPED CAPACITOR	JPH09502630 (A)	3/18/1997			JP19950509178	US19930123321 19930917; WO1994U509145 19940812
GAMMA MATCHED, HELICAL dipole microwave antenna with tubular-shaped capacitor	AU678624 (B2) EP0634946 (A4); EP0634946 (B1); EP0634946 (A1)	6/5/1997	RUDIE ERIC N.; KLUGE STANLEY E	UROLOGIX INC	AU19940679260	US19930123321 19930917; WO1994U509145 19940812
GAMMA MATCHED, HELICAL DIPOLE MICROWAVE ANTENNA		1/25/1995	RUDIE ERIC N.[US]; NEILSON BRUCE H.	UROLOGIX INC.[US]	EP19930907080	WO1993U501780 19930301; US19920847915 19920306
Liquid coolant supply system	AU2678897 (A)	11/12/1997	KAUPHUSMAN JAMES V NORSTED STEVEN W.[US]; NEILSON BRUCE H.[US]; KLUGE STANLEY E.[US]; DANN MITCHELL.[US]; BURGETT JAMES E.[US]; REID JOHN M.[US]; KAUPHUSMAN JAMES V.[US]; RUDIE ERIC N.[US]	UROLOGIX INC	AU19970026788D	US19960637405 19960425; WO1997U504633 19970421
METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA WITH THERMAL THERAPY	CA2222125 (A1)	1/16/1997		UROLOGIX INC.[US]	CA19960722125	US19950494320 19950626

TRADEMARK
REEL: 005857 FRAME: 0777

Title	Publication number	Publication date	Inventor(s)	Applicant(s)	Application number	Priority number(s)
Method for treating benign prostatic hyperplasia with thermal therapy	AU6393896 (A)	1/30/1997	RUDIE ERIC N.[US]; DANN MITCHELL.[US]; REID JOHN M.[US]; NELSON BRUCE H.[US]; KAUPHUSMAN JAMES V.[US]; BURGETT JAMES E.[US]; KLUGE STANLEY E.[US]; NORSTED STEVEN W.[US]	UROLOGIX INC.[US]	AU19960063938D	US19950494320 19950626; WO1996US10870 19960624
METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA WITH THERMAL THERAPY	EP0241864 (A1)	5/26/1998	RUDIE ERIC N.[US]; DANN MITCHELL.[US]; REID JOHN M.[US]; NELSON BRUCE H.[US]; KAUPHUSMAN JAMES V.[US]; BURGETT JAMES E.[US]; KLUGE STANLEY E.[US]; NORSTED STEVEN W.[US]	UROLOGIX INC.[US]	EP19960923424	US19950494320 19950626; WO1996US10870 19960624
Method for treating benign prostatic hyperplasia with thermal therapy	AU702662 (B2)	8/12/1999	RUDIE ERIC N.[US]; DANN MITCHELL.[US]; REID JOHN M.[US]; NELSON BRUCE H.[US]; KAUPHUSMAN JAMES V.[US]; BURGETT JAMES E.[US]; KLUGE STANLEY E.[US]; NORSTED STEVEN W.[US]	UROLOGIX INC.[US]	AU19960063938	US19950494320 19950626; WO1996US10870 19960624
METHOD OF CONTROLLING THERMAL THERAPY	CA2354587 (A1)	6/15/2000	BURGETT JAMES E.[US]; LARSON THAYNE R.[US]; FLACHMAN JONATHAN L.[US]; RUDIE ERIC N.[US]	UROLOGIX INC.[US]	CA19992354587	US19980210033 19981211; WO1999US29381 19991210
Method of controlling thermal therapy	AU3118800 (A)	6/26/2000	RUDIE ERIC N.; FLACHMAN JONATHAN L.; BURGETT JAMES E.; LARSON THAYNE R.	UROLOGIX INC	AU20000031188D	US19980210033 19981211; WO1999US29381 19991210
Microwave antenna for arterial microwave applicator	AU3368597 (A)	1/7/1998	RUDIE ERIC N.[US]	UROLOGIX INC.[US]	AU19970033685D	US19960672505 19960617; WO1997US08519 19970610
SELECTIVE MODULATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, AND METHODS FOR THE USE THEREOF	CA2218955 (A1)	10/31/1996	EVANS RONALD M.[US]; FORMAN BARRY M.[US]	SALK INST FOR BIOLOGICAL STUDI.[US]	CA19962218955	US19950428559 19950425; US19950465375 19950605

TRADEMARK

REEL: 005857 FRAME: 0778

Title	Publication number	Publication date	Inventor(s)	Applicant(s)	Application number	Priority number(s)
SELECTIVE MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-GAMMA, AND METHODS FOR THE USE THEREOF	EP06271818 (A2)	2/11/1998	EVANS RONALD M.[US]; FORMAN BARRY M.[US]	SALK INST FOR BIOLOGICAL STUDI.[US]	EPI19960912936	US19950465375 19950605; WO1996US05465 19960418; US19950478559 19950425
Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof	AU705912 (B2)	6/3/1999	EVANS RONALD M.; FORMAN BARRY M.	SALK INST FOR BIOLOGICAL STUDI	AU19960055592	US19950465375 19950605; WO1996US05465 19960418; US19950428559 19950425
System and method for transurethral heating with rectal cooling	AU78265998 (A)	2/10/1999	FLACHMAN JONATHAN L	UROLOGIX INC	AU19980078269D	WO1998US11638 19980609; US19970897115 19970714
System for prostate treatment while preventing urethral constriction	AU8286998 (A)	3/22/1999	MCGRATH JONATHAN R; DANN MITCHELL	UROLOGIX INC	AU19980082889D	US19970920744 19970829; WO1998US14350 19980810
THERMAL THERAPY CATHETER	CA2365131 (A1)	10/5/2000	HJELLE AARON.[US]; STOCKMOE SCOTT.[US]; RUDIE ERIC N.[US]; EBNER BRUCE W.[US]; CRABB JOEL.[US]; FLACHMAN JONATHAN L.[US]	UROLOGIX INC.[US]	CA20002365131	US19990303259 19990430; WO2000US07769 20000323; US19990126330P 19990326 US19990126330P 19990326; US19990303259 19990430; WO2000US07769 20000323
Thermal therapy catheter	AU3914900 (A)	10/16/2000	RUDIE ERIC N.; STOCKMOE SCOTT; HJELLE AARON; EBNER BRUCE W; CRABB JOEL	UROLOGIX INC	AU20000039149D	WO2000US07769 20000323; US19990126330P 19990326; US19990303259 19990430
THERMAL THERAPY CATHETER	AT516765 (T)	8/15/2011	RUDIE ERIC.[US]; HJELLE AARON.[US]; EBNER BRUCE.[US]; CRABB JOEL.[US]	UROLOGIX INC.[US]	AT20000916317T	US19990303259 19990430 US19960621634 19960326; WO1997US05066 19970326
Voltage controlled variable tuning antenna	AU2347597 (A)	10/17/1997	RUDIE ERIC N	UROLOGIX INC	AU19970023475D	WO1997US05066 19970326

U.S. Patents and Applications

5645528

12/378045 (abd)

11/800704 (abd)

10/247080 (abd)

TRADEMARK
REEL: 005857 FRAME: 0779

US AND FOREIGN ISSUED PATENTS/APPLICATIONS

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ³
U520.102.101 U143.12-0002	MICROWAVE THERAPY APPARATUS	10/01/99	08/07/01	6,272,384
U520.103.101 U143.12-0003	METHOD AND APPARATUS FOR THE SURGICAL TREATMENT OF TISSUES BY THERMAL EFFECT AND IN PARTICULAR THE PROSTATE USING A URETHRAL MICROWAVE EMITTING PROBE MEANS	03/12/91	08/10/93	5,234,004*
U520.104.101 U143.12-0004	METHOD AND APPARATUS FOR THE SURGICAL TREATMENT OF TISSUES BY THERMAL EFFECT AND IN PARTICULAR THE PROSTATE USING A URETHRAL MICROWAVE EMITTING PROBE MEANS (C-I-P, filed 11/17/89)	05/24/93	01/2/96	5,480,417*
U520.105.101 U143.12-0005	ARM HAVING AN END MOVABLE IN TRANSLATION AND THERAPEUTIC TREATMENT FOR APPARATUS CONSTITUTING AN APPLICATION THEREOF	04/03/91	12/15/92	5,170,790*
U520.106.101 U143.12-0006	METHOD OF AUTOMATICALLY MEASURING THE VOLUME OF A TUMOR OR OF A GLAND IN PARTICULAR THE PROSTATE A MEASURING DEVICE AND A METHOD AND APPARATUS CONSTITUTING AND APPLICATION THEREOF	04/03/91	01/12/93	5,178,148*
U520.107.101 U143.12-0007	TRANSRECTAL PROBE (Cont., fled 4/3/91)	01/21/93	04/11/95	5,404,881*
U520.108.101 U143.12-0008	URETHRAL PROBE AND APPARATUS FOR THE THERAPEUTIC TREATMENT OF THE PROSTATE BY THERMOTHERAPY	10/06/92	04/23/96	5,509,929*

³ Abandoned, expired or closed indicated by *

DBC FILE NO.	TITLE	DATE FILED	DATE ISSUED	PATENT NO. ³
U520.101.291 U143.13-0001 (FOREIGN)	METHOD & APPARATUS FOR THE THERAPEUTICAL TREATMENT BY THERMAL EFFECT EPC	App. 91.1134815	03/19/08	459535
U520.101.321 Germany	METHOD & APPARATUS FOR THE THERAPEUTICAL TREATMENT BY THERMAL EFFECT	06/12/08		DE6892955612*
U520.101.751 United Kingdom	METHOD & APPARATUS FOR THE THERAPEUTICAL TREATMENT BY THERMAL EFFECT	04/08/08		GB459535*

Patent Applications:

COUNTRY	TITLE	APPLICATION NUMBER	DATE FILED
US	NEUROMODULATION SYSTEM AND RELATED METHODS	13/851,760	Mar 27, 2013
EP	NEUROMODULATION SYSTEM AND RELATED METHODS	13767948.6	Mar 27, 2013

OTHER FOREIGN PATENT APPLICATIONS

DBC FILE NO.	TITLE	COUNTRY	DATE OPEN	DATE FILED	SERIAL NO. ⁴
U510.153.441 U43.13-0072	(Millennium) THERMAL THERAPY CATHETER	JAPAN	09/07/01	05/23/00	2000-607565*
U510.154.291 U43.13-0078	MICROWAVE ABLATION DEVICE (U43.12-0072 Provisional U43.12-0074 Utility))	EP: AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, SE	09/17/02	09/19/02	02 761711.7*
U510.155.441 U43.13-0082	MICROWAVE ABLATION DEVICE	JAPAN	02/19/04	09/19/02	2003-528211*

* Abandoned, expired or closed indicated by *